PROCEPT BioRobotics Corporation(PRCT) Stock Research - Grey Stern Research

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis

$96.76 (0.29%)

PRCT Financial Performance


Use the table below to view PROCEPT BioRobotics Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $96.48 -
52 Week Low $36.52 -
52 Week High $103.81 -
Market Cap $5.2 Billion 1/16
Gross Margin 63% 13/16
Profit Margin -36% 13/16
EBITDA margin -32% 12/16
Q3 - 2024 Revenue $58.4 Million 6/16
Q3 - 2024 Earnings -$21.0 Million 15/16
Q3 - 2024 Free Cash Flow -$19.0 Million 16/16
Trailing 4 Quarters Revenue $199.8 Million 7/16
Trailing 4 Quarters Earnings -$100.1 Million 15/16
Quarterly Earnings Growth 15% 9/16
Annual Earnings Growth 0% 12/16
Quarterly Revenue Growth 66% 1/16
Annual Revenue Growth 49% 2/16
Cash On Hand $196.8 Million 2/16
Short Term Debt $1.8 Million 5/16
Long Term Debt $51.4 Million 10/16

PROCEPT BioRobotics Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare PROCEPT BioRobotics Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 4/16
PS 26.26 1/16
PB 21.76 3/16
PC 26.67 7/16
Liabilities to Equity 0.55 11/16
ROA -0.27 14/16
ROE -0.41 10/16
Current Ratio 2.81 6/16
Quick Ratio 1.48 4/16
Long Term Debt to Equity 0.21 13/16
Debt to Equity 0.21 13/16
Burn Rate 8.38 2/16
Cash to Cap 0.04 8/16
CCR 0.91 6/16
EV to EBITDA -275.73 14/16
EV to Revenue 25.53 1/16

Company Details

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

CEO:

Website: https://www.procept-biorobotics.com

Address: 900 Island Drive Redwood City, CA

Exchange: NASDAQ Global Market

Industry: Medical Devices

PROCEPT BioRobotics Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to PROCEPT BioRobotics Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
LivaNova PLC LIVN $2.8 Billion
AxoGen, Inc. AXGN $635.5 Million
Integer Holdings Corporation ITGR $4.7 Billion
CONMED Corporation CNMD $2.3 Billion
Surmodics, Inc. SRDX $565.7 Million
Orthofix Medical Inc. OFIX $739.1 Million
OrthoPediatrics Corp. KIDS $634.0 Million
Establishment Labs Holdings Inc. ESTA $1.3 Billion
SI-BONE, Inc. SIBN $546.0 Million
Pulmonx Corporation LUNG $261.0 Million
NeuroPace, Inc. NPCE $356.1 Million
Treace Medical Concepts, Inc. TMCI $532.6 Million
Sight Sciences, Inc. SGHT $195.9 Million
RxSight, Inc. RXST $1.8 Billion
Paragon 28, Inc. FNA $856.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
PRCT Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 58.4 Million -$21.0 Million
Q2 2024 $ 53.4 Million -$25.6 Million
Q1 2024 $ 44.5 Million -$26.0 Million
Q4 2023 $ 43.6 Million -$27.5 Million
Q3 2023 $ 35.1 Million -$24.6 Million
Q2 2023 $ 33.1 Million -$25.3 Million
Q1 2023 $ 24.4 Million -$27.7 Million
Q4 2022 $ 23.8 Million -$31.3 Million

View All

PRCT Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $196.8 Million $374.1 Million $51.4 Million $241.2 Million
Q2 2024 $214.1 Million $374.4 Million $81.0 Million $251.8 Million
Q1 2024 $225.6 Million $382.9 Million $81.4 Million $264.0 Million
Q4 2023 $257.2 Million $404.7 Million $79.2 Million $280.8 Million
Q3 2023 $287.1 Million $421.1 Million $78.0 Million $299.4 Million
Q2 2023 $149.7 Million $272.4 Million $80.8 Million $155.9 Million
Q1 2023 $181.0 Million $284.5 Million $80.0 Million $173.1 Million
Q4 2022 $221.9 Million $309.3 Million $77.3 Million $197.1 Million

View All

PRCT Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$19.0 Million -$246,000 -$17.3 Million
Q2 2024 -$16.8 Million -$1.0 Million -$11.5 Million
Q1 2024 -$34.2 Million -$1.9 Million -$31.6 Million
Q4 2023 -$33.5 Million -$8.7 Million -$30.6 Million
Q3 2023 -$24.7 Million -$5.8 Million $137.4 Million
Q2 2023 -$33.7 Million -$5.4 Million -$31.3 Million
Q1 2023 -$41.3 Million -$5.3 Million -$40.9 Million
Q4 2022 -$26.0 Million -$866,000 -$27.4 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions